Life sciences partner Katherine Wang (Shanghai) examined new China regulations that impact drug and device inspection in an Asia Pacific Biotech News article published on Feb 11.
The regulations are designed to verify whether foreign drug and device companies’ research and manufacturing processes adhere to medical product standards in China. The regulations seek to verify authenticity, reliability and compliance of R&D and manufacturing activities.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.